Answers are grounded in this paper and cite their sources.
Randomized trial explores neural mechanisms affecting tumor growth and treatment efficacy, suggesting new therapy combinations.
The nervous system is now recognized as an enabling hallmark of cancer biology. Neural inputs drive tumor growth in both central nervous system tumors and extracranial tumors through different mechanisms, including synaptic signaling, adrenergic regulation, perineural invasion, neuropeptides, immune remodeling, and bioelectric mechanisms. These insights have facilitated repurposing of neuroactive agents that are now in clinical trials as adjuncts to standard cancer therapy. The central translational challenge now is how to match the right neural circuit to the right patient and to pair appropriate neuromodulators with immunotherapy in combinations designed to restore, rather than merely supplement, antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Pasvolsky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: